μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief

Psychopharmacology

Volumn 222, Issue 4, 2012, Pages 701-708

  Falcone, Mary ^a,b   Gold, Allison B ^b   Wileyto, E Paul ^b   Ray, Riju ^b   Ruparel, Kosha ^b   Newberg, Andrew ^c   Dubroff, Jacob ^d   Logan, Jean ^e   Zubieta, Jon Kar ^f   Blendy, Julie A ^a   Lerman, Caryn ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e BROOKHAVEN NATIONAL LABORATORY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Opioid receptor; Affect regulation; Amygdala; Smoking motivation

Indexed keywords

CARFENTANIL C 11; MU OPIATE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AFFECT; AMYGDALOID NUCLEUS; ARTICLE; CIGARETTE SMOKING; FEMALE; HUMAN; MALE; MOOD CHANGE; MOTIVATION; NEUROIMAGING; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SELF REPORT; SMOKING CESSATION;

ADULT; AFFECT; AMYGDALA; CARBON RADIOISOTOPES; DOUBLE-BLIND METHOD; FEMALE; FENTANYL; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MOTIVATION; NICOTINE; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, MU; SMOKING;

EID: 84864487722     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2673-5     Document Type: Article

References (66)

1. Balerio GN, Aso E, Maldonado R (2005) Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) 181:260-269
2. Benowitz NL, Jacob P 3rd, Herrera B (2006) Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clin Pharmacol Ther 80:703-714
3. Berrendero F, Kieffer BL, Maldonado R (2002) Attenuation of nicotineinduced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci 22:10935-10940
4. Boyadjieva NI, Sarkar DK (1997) The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci 61:PL59-PL66
5. Brody AL, Mandelkern MA, Costello MR, Abrams AL, Scheibal D, Farahi J, London ED, Olmstead RE, Rose JE, Mukhin AG (2009) Brain nicotinic acetylcholine receptor occupancy: Effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol 12:305-316
6. CDC (2009) Center for Disease Control: Cigarette smoking among adults and trends in smoking cessation-United States, 2008. MMWR Morb Mortal Wkly Rep 58:1227-1232
7. Colvin PJ, Mermelstein RJ (2010) Adolescents' smoking outcome expectancies and acute emotional responses following smoking. Nicotine Tob Res 12:1203-1210
8. Conklin CA, Perkins KA (2005) Subjective and reinforcing effects of smoking during negative mood induction. J Abnorm Psychol 114:153-164
9. Costa PT Jr, McCrae RR, Bosse R (1980) Smoking motive factors: A review and replication. Int J Addict 15:537-549
10. Davidson RJ, Irwin W (1999) The functional neuroanatomy of emotion and affective style. Trends Cogn Sci 3:11-21
11. Diekhof EK, Geier K, Falkai P, Gruber O (2011) Fear is only as deep as the mind allows a coordinate-based meta-Analysis of neuroimaging studies on the regulation of negative affect. NeuroImage 58:275-285
12. Diener E, Emmons RA (1984) The independence of positive and negative affect. J Pers Soc Psychol 47:1105-1117
13. Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O'Malley SS (2010) Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug Alcohol Depend 112:1-8
14. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, Koeppe R, Zubieta JK (2007) Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 61:101-110
15. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119-1127
16. Hirvonen J, Aalto S, Hagelberg N, Maksimow A, Ingman K, Oikonen V, Virkkala J, Nagren K, Scheinin H (2009) Measurement of central mu-opioid receptor binding in vivo with PET and [11C] carfentanil: A test-retest study in healthy subjects. Eur J Nucl Med Mol Imaging 36:275-286
17. Horn D, Waingrow S (1966) Some dimensions of a model for smoking behavior change. Am J Public Health Nations Health 56(Suppl 56):21-26
18. Houdi AA, Pierzchala K, Marson L, Palkovits M, Van Loon GR (1991) Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12:161-166
19. Hutchison KE, Monti PM, Rohsenow DJ, Swift RM, Colby SM, Gnys M, Niaura RS, Sirota AD (1999) Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology (Berl) 142:139-143
20. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE (2003) Linearized reference tissue parametric imaging methods: Application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096-1112
21. Juliano LM, Fucito LM, Harrell PT (2011) The influence of nicotine dose and nicotine dose expectancy on the cognitive and subjective effects of cigarette smoking. Exp Clin Psychopharmacol 19:105-115
22. Karp JS, Surti S, Daube-Witherspoon ME, Freifelder R, Cardi CA, Adam LE, Bilger K, Muehllehner G (2003) Performance of a brain PET camera based on anger-logic gadolinium oxyorthosilicate detectors. J Nucl Med 44:1340-1349
23. Kassel JD, Evatt DP, Greenstein JE, Wardle MC, Yates MC, Veilleux JC (2007) The acute effects of nicotine on positive and negative affect in adolescent smokers. J Abnorm Psychol 116:543-553
24. Kim MJ, Loucks RA, Palmer AL, Brown AC, Solomon KM, Marchante AN, Whalen PJ (2011) The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav Brain Res 223:403-410
25. Lee MR, Gallen CL, Zhang X, Hodgkinson CA, Goldman D, Stein EA, Barr CS (2011) Functional Polymorphism of the Mu-Opioid Receptor Gene (OPRM1) Influences Reinforcement Learning in Humans. PLoS One 6:e24203
26. Lerman C, Audrain-McGovern J (2010) Reinforcing effects of smoking: more than a feeling. Biol Psychiatry 67:699-701
27. Lerman C, Audrain J, Orleans CT, Boyd R, Gold K, Main D, Caporaso N (1996) Investigation of mechanisms linking depressed mood to nicotine dependence. Addict Behav 21:9-19
28. Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, Shields PG (1998) Depression and self-medication with nicotine: The modifying influence of the dopamine D4 receptor gene. Health Psychol 17:56-62
29. Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67:219-223
30. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-Term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4:184-192
31. Mague SD, Blendy JA (2010) OPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108:172-182
32. Mahler SV, Berridge KC (2009) Which cue to "want?" Central amygdala opioid activation enhances and focuses incentive salience on a prepotent reward cue. J Neurosci 29:6500-6513
33. Marty MA, Erwin VG, Cornell K, Zgombick JM (1985) Effects of nicotine on beta-endorphin, alpha MSH, and ACTH secretion by isolated perfused mouse brains and pituitary glands, in vitro. Pharmacol Biochem Behav 22:317-325
34. Mills RH, Sohn RK, Micevych PE (2004) Estrogen-induced mu-opioid receptor internalization in the medial preoptic nucleus is mediated via neuropeptide Y-Y1 receptor activation in the arcuate nucleus of female rats. J Neurosci 24:947-955
35. Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC (2007) Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J 7:353-361
36. O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D,Wu R, Makuch R, Jatlow P (2006) A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 166:667-674
37. Perkins KA, Giedgowd GE, Karelitz JL, Conklin CA, Parzynski CS (2011) Expectancy for negative affect relief due to smoking may not be predictive under acute mood situations. Exp Clin Psychopharmacol
38. Perkins KA, Karelitz JL, Giedgowd GE, Conklin CA, SayetteMA (2010) Differences in negative mood-induced smoking reinforcement due to distress tolerance, anxiety sensitivity, and depression history. Psychopharmacology (Berl) 210:25-34
39. Perkins KA, Lerman C, Grottenthaler A, Ciccocioppo MM, Milanak M, Conklin CA, Bergen AW, Benowitz NL (2008) Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol 19:641-649
40. Pessoa L (2010) Emergent processes in cognitive-emotional interactions. Dialogues Clin Neurosci 12:433-448
41. Pfeiffer A, Pasi A, Mehraein P, Herz A (1982) Opiate receptor binding sites in human brain. Brain Res 248:87-96
42. Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, Lynch KG, O'Malley S, Berrettini WH, Lerman C (2006) Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) 188:355-363
43. Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C (2007) Genetic variation in mu-opioidreceptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine Tob Res 9:1237-1241
44. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C (2011) Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A 108:9268-9273
45. Ribeiro SC, Kennedy SE, Smith YR, Stohler CS, Zubieta JK (2005) Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors. Prog Neuropsychopharmacol Biol Psychiatry 29:1264-1280
46. Rose JE (2006) Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) 184:274-285
47. Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S, Zubieta JK (2007) Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32:450-457
48. Shiffman S (1993) Assessing smoking patterns and motives. J Consult Clin Psychol 61:732-742
49. Shiffman S, Hufford M, Hickcox M, Paty JA, Gnys M, Kassel JD (1997) Remember that? A comparison of real-Time versus retrospective recall of smoking lapses. J Consult Clin Psychol 65:292-300
50. Shiffman S, Prange M (1988) Self-reported and self-monitored smoking patterns. Addict Behav 13:201-204
51. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM (2004) Advances in functional and structural MR image analysis and implementation as FSL. Neuro-Image 23(Suppl 1):S208-S219
52. Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK (2006) Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 26:5777-5785
53. Strasser AA, Ashare RL, Kozlowski LT, Pickworth WB (2005a) The effect of filter vent blocking and smoking topography on carbon monoxide levels in smokers. Pharmacol Biochem Behav 82:320-329
54. Strasser AA, Kaufmann V, Jepson C, Perkins KA, Pickworth WB, Wileyto EP, Rukstalis M, Audrain-McGovern J, Lerman C (2005b) Effects of different nicotine replacement therapies on postcessation psychological responses. Addict Behav 30:9-17
55. Strasser AA, Lerman C, Sanborn PM, Pickworth WB, Feldman EA (2007) New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. Drug Alcohol Depend 86:294-300
56. Tate JC, Stanton AL (1990) Assessment of the validity of the Reasons for Smoking scale. Addict Behav 15:129-135
57. Walsh Z, Epstein A, Munisamy G, King A (2008) The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. J Addict Dis 27:65-72
58. Walters CL, Cleck JN, Kuo YC, Blendy JA (2005) Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46:933-943
59. Wewers ME, Dhatt RK, Snively TA, Tejwani GA (1999) The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res 822:107-113
60. WHO (2009) World Health Organization. WHO Report on the global tobacco epidemic.
61. Zhang L, Kendler KS, Chen X (2006) The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct 2:28
62. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Nichols TE, Stohler CS (2005) Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 25:7754-7762
63. Zubieta JK, Dannals RF, Frost JJ (1999) Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry 156:842-848
64. Zubieta JK, Ketter TA, Bueller JA, Xu Y, Kilbourn MR, Young EA, Koeppe RA (2003) Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry 60:1145-1153
65. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS (2001) Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293:311-315
66. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS (2002) mu-opioid receptormediated antinociceptive responses differ in men and women. J Neurosci 22:5100-5107